Arvalus receives Helmholtz Enterprise grant

Written By Christian Brandstetter

In November we received a positive funding notice for the Helmholtz Enterprise spin-off grant. With this funding for the next 14 months, we can reach the next important milestones on our entrepreneurial journey and take the next step towards a spin-off.

Read more about the Helmholtz Enterprise spin-off grant here.

Christian Brandstetter https://www.arvalus-therapeutics.com
Previous

Helmholtz Enterprise Kick-off in Berlin
Next

INCATE has selected Arvalus as a promising startup to tackle antimicrobial resistance